Table 3.
Immune-relevant genes specifically up-regulated by sub-cutaneous melanomas
| Clone ID | Location | Gene | AVERAGE | t-test (p2-value) | ||
| SQ | Other | SQ vs Oth | Me vs Oth | |||
| 295868 | 1p34 | LAPTM5 | 0.43 | -0.68 | 2.00E-04 | 3.00E-04 |
| P37265 | 1p34.3 | LCK | 0.55 | -0.58 | 1.00E-04 | 6.00E-06 |
| 2563224 | 1p36.2 | PIK3CD | 0.8 | -0.88 | 3.00E-07 | 5.00E-15 |
| 842871 | 1q12 | PDE4DIP | 0.58 | -0.21 | 5.00E-04 | 9.00E-05 |
| 773509 | 1q21.3 | SNX27 | 1.05 | -0.88 | 9.00E-11 | 7.00E-16 |
| 701332 | 1q22 | IFI16 | 0.25 | -0.39 | 2.00E-04 | 1.00E-05 |
| 472009 | 1q42.1 | DISC1 | 0.35 | -0.26 | 1.00E-07 | 9.00E-08 |
| 746229 | 2q11.2-q | MAP4K4 | 0.15 | -0.24 | 7.00E-04 | 6.00E-05 |
| 840466 | 2q12-q13 | MARCO | 0.34 | -0.28 | 3.00E-05 | 2.00E-04 |
| 328542 | 2q24-q3 | GALNT3 | 0.51 | -0.4 | 4.00E-04 | 1.00E-03 |
| 825715 | 2q37.1 | SP110 | 0.71 | -0.59 | 9.00E-07 | 3.00E-09 |
| 283023 | 3p21 | CX3CR1 | 0.31 | -0.34 | 2.00E-05 | 4.00E-10 |
| 1605539 | 4p16.3 | IDUA | 0.27 | -0.29 | 4.00E-06 | 6.00E-06 |
| 724932 | 5q35 | GRK6 | 0.43 | -0.19 | 4.00E-05 | 3.00E-05 |
| 753587 | 6p21.3 | BTN3A3 | 0.49 | -0.43 | 2.00E-05 | 5.00E-06 |
| 753236 | 6p21.3 | TAP2 | 0.31 | -0.42 | 2.00E-04 | 1.00E-07 |
| 752557 | 6p21.3 | GPSM3 | 0.42 | -0.42 | 1.00E-04 | 3.00E-06 |
| 2549448 | 6q21 | FYN | 0.6 | -0.45 | 1.00E-07 | 2.00E-07 |
| 2306953 | 8q13.3 | LY96 | 1.01 | -0.32 | 3.00E-06 | 2.00E-08 |
| 645332 | 10p12 | NEBL | 0.23 | -0.23 | 6.00E-04 | 2.00E-04 |
| 1631391 | 11p11.2 | BHC80 | 0.35 | -0.29 | 8.00E-04 | 4.00E-04 |
| 686164 | 11p11.2 | DGKZ | 0.44 | -0.21 | 2.00E-04 | 4.00E-04 |
| 487115 | 11p11.2 | PTPRJ | 0.78 | -0.4 | 3.00E-09 | 5.00E-07 |
| 151430 | 11p13 | CD44 | 0.71 | -0.22 | 1.00E-03 | 2.00E-05 |
| 740117 | 11p15.5 | IRF-7 | 0.53 | -0.3 | 4.00E-05 | 3.00E-04 |
| P33303 | 11p15.5 | LSP1 | 0.55 | -0.4 | 1.00E-03 | 2.00E-05 |
| 1850690 | 11q23.3 | BLR1 | 0.36 | -0.36 | 6.00E-05 | 2.00E-04 |
| 2120815 | 12p12-p1 | KLRG1 | 0.51 | -0.44 | 1.00E-04 | 5.00E-04 |
| 34637 | 12p13 | CD27 | 0.72 | -0.54 | 4.00E-04 | 1.00E-04 |
| 1517162 | 12p13.2- | KLRK1 | 0.55 | -0.53 | 5.00E-04 | 6.00E-04 |
| 1569551 | 12q13.11 | CSAD | 0.37 | -0.45 | 2.00E-04 | 6.00E-06 |
| 429186 | 13q21.33 | LMO7 | 0.41 | -0.37 | 5.00E-06 | 4.00E-19 |
| P41256 | 15q26.3 | IL-16 | 0.64 | -0.58 | 4.00E-05 | 2.00E-06 |
| P14913 | 16p11 | IL-21R1 | 0.48 | -0.43 | 6.00E-06 | 6.00E-04 |
| P07382 | 16p11.2 | ITGAL | 0.55 | -0.48 | 2.00E-05 | 3.00E-06 |
| P12753 | 16p13.3 | NK4; | 0.32 | -0.3 | 4.00E-05 | 3.00E-06 |
| 206795 | 17p | ASGR2 | 0.57 | -0.53 | 8.00E-05 | 6.00E-06 |
| 488575 | 17p11.2 | ULK2 | 0.35 | -0.17 | 3.00E-06 | 1.00E-04 |
| 155717 | 17q23 | CD79B | 0.44 | -0.41 | 3.00E-05 | 2.00E-11 |
| 156343 | 17q24.2 | MAP3K3 | 0.62 | -0.46 | 4.00E-06 | 7.00E-11 |
| P38436 | 17q25 | CARD14 | 0.54 | -0.33 | 4.00E-08 | 2.00E-08 |
| 1551273 | 19p12 | MEF2B | 0.19 | -0.21 | 7.00E-05 | 1.00E-09 |
| 814377 | 19p13.1 | BRD4 | 0.9 | -0.7 | 6.00E-06 | 2.00E-16 |
| 2010562 | 19p13.3 | MYO1F | 0.55 | -0.62 | 9.00E-04 | 7.00E-05 |
| 824384 | 19p13-q1 | CD37 | 0.64 | -0.74 | 1.00E-03 | 7.00E-04 |
| 788272 | 19q13.1 | CLC | 0.61 | -0.64 | 7.00E-06 | 3.00E-06 |
| 815239 | 19q13.13 | ARHGEF1 | 0.38 | -0.42 | 3.00E-05 | 1.00E-04 |
| 683276 | 19q13.33 | CARD8 | 0.86 | -0.64 | 1.00E-08 | 3.00E-05 |
| 277906 | 19q13.4 | LILRB1 | 0.89 | -0.51 | 4.00E-04 | 5.00E-04 |
| 202897 | 19q13.4 | LILRB2 | 0.72 | -0.61 | 4.00E-04 | 1.00E-06 |
| 2072768 | 20q12 | NCOA3 | 0.69 | -0.36 | 4.00E-06 | 2.00E-05 |
SQ = Average Cy5/Cy3 ratios of10 frozen samples from cutaneous and subcutaneous metastases as described in Table I. Oth = Sample from 80 primary tumors other than melanoma and RCC with the exclusion, in this table of lymph nodal metastases from colorectal cancer (see Table I). Complete and extended gene name is available at http://www.societymelanomaresearch.org